# A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

> **NCT06153095** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Lyell Immunopharma, Inc.**

## Conditions studied

- Systemic Lupus Erythematosus
- Lupus Nephritis

## Interventions

- **BIOLOGICAL:** IMPT-514
- **BIOLOGICAL:** IMPT-514
- **BIOLOGICAL:** IMPT-514

## Key facts

- **NCT ID:** NCT06153095
- **Lead sponsor:** Lyell Immunopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-02-15
- **Primary completion:** 2025-01-09
- **Final completion:** 2025-01-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153095, "A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06153095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*